Semaglutide for Weight Loss: Medical Criteria & Provider Evalu...

Q: Can I get semaglutide just because I want to lose weight, or do I need specific medical criteria?

Semaglutide requires provider evaluation of BMI, metabolic biomarkers, and medical history—not weight alone. Providers assess cardiovascular risk, kidney function, and contraindications to determine if semaglutide is medically appropriate for your individual health profile.

Q: What happens if I have a history of pancreatitis or gallbladder disease?

These conditions require careful provider discussion. History of pancreatitis is generally a contraindication; gallbladder disease demands individual risk-benefit assessment. Your provider may recommend imaging or closer monitoring before starting treatment.

Q: How much does compounded semaglutide cost through PlexusDx?

PlexusDx compounded semaglutide injection ranges from $149 per month, and oral formulations start at $209 per month. All products come from licensed 503A compounding pharmacies. Pricing reflects your specific dosage and formulation choice.

Q: What blood work should I have before starting semaglutide?

Standard baseline labs include fasting glucose, HbA1c, lipid panel, kidney function (eGFR), liver enzymes, and blood pressure. If personal or family history suggests thyroid concerns, TSH and calcitonin may be ordered. Your provider determines the specific panel based on your health profile.

Q: How does the Precision Peptide Genetic Test help with semaglutide candidacy?

The test reveals predispositions in GLP1R, GIPR, FTO, and MC4R pathways that may inform your provider's treatment strategy. Genetic context combined with biomarkers and medical history supports more personalized eligibility discussion—not prediction of exact response or guaranteed outcomes.

Last reviewed: May 14, 2026

Last updated: May 14, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Obtaining semaglutide for weight loss requires more than requesting a prescription—it demands a qualified healthcare provider's clinical evaluation of your metabolic health, cardiovascular status, and individual risk profile. Unlike off-label prescribing models, responsible semaglutide access depends on baseline assessment of factors including fasting glucose, lipid panels, kidney function, and personal or family history of thyroid or pancreatic disease.

Understanding what providers assess during this evaluation empowers you to prepare meaningful conversations with your healthcare team. PlexusDx supports precision-wellness by helping patients recognize relevant biomarkers and genetic predispositions that inform personalized treatment candidacy, rather than assuming semaglutide eligibility based solely on weight or BMI.

Medical Eligibility Criteria Providers Evaluate Before Starting Semaglutide

Semaglutide is indicated for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related conditions; however, provider assessment extends far beyond weight metrics. Providers evaluate fasting glucose, HbA1c, liver enzymes, kidney function, and blood pressure to establish baseline metabolic health and identify contraindications or safety considerations.

Personal or family history of medullary thyroid carcinoma (MTC), multiple endocrine neoplasia type 2 (MEN2), pancreatitis, gallbladder disease, or diabetic retinopathy requires careful risk-benefit discussion. Concurrent medications, pregnancy status, and recent bariatric surgery are also factored into provider eligibility determinations.

Key Biomarkers and Baseline Assessments That Guide Treatment Decisions

Before initiating semaglutide, providers typically order comprehensive metabolic panels to establish baseline insulin sensitivity, glucose tolerance, and cardiovascular risk markers. These biomarkers help providers assess whether semaglutide aligns with your individual metabolic profile and inform dosing strategy.

Biomarker	Why Providers Assess It
Fasting glucose and HbA1c	Establishes baseline glucose control and diabetes risk; informs GLP-1 response prediction
Lipid panel (total, LDL, HDL, triglycerides)	Cardiovascular risk assessment; semaglutide may improve lipid profile in some patients
Kidney function (eGFR, creatinine)	Determines dose safety; GLP-1 agonists require dose adjustment if eGFR <15
Liver function tests (ALT, AST, bilirubin)	Screens for hepatic impairment that may affect medication metabolism
TSH and calcitonin (if indicated by history)	Rules out thyroid disease or familial thyroid cancer predisposition before GLP-1 use
Blood pressure	Baseline cardiovascular status; semaglutide may lower BP in some patients

How Genetic Predispositions Can Inform Your Provider Conversation

Individual variation in GLP-1 receptor signaling and metabolic pathways influences treatment response and tolerability. Genetic markers in GLP1R, GIPR, FTO, and MC4R genes may provide context about your inherent metabolic tendencies and how your body may respond to GLP-1 agonists.

The Precision Peptide Genetic Test identifies predispositions in these peptide pathways—such as variants in GLP1R rs6923761 or FTO rs9939609—that may help provide context for your provider's treatment planning. This information should be interpreted with a qualified healthcare provider and is not a predictor of exact medication response or guaranteed weight loss outcomes.

Safety Considerations and Who Should Not Use Semaglutide Without Provider Approval

Absolute contraindications include personal history of medullary thyroid cancer, multiple endocrine neoplasia type 2, or severe hypersensitivity to semaglutide components. Relative contraindications requiring careful provider evaluation include uncontrolled hypertension, recent acute pancreatitis, advanced diabetic retinopathy, or severe kidney disease.

Patients with history of gallbladder disease, those planning pregnancy, or those on concurrent medications affecting glucose metabolism should disclose these details to their provider. Honest communication about medical history, lifestyle, and treatment expectations ensures semaglutide candidacy assessment reflects your complete clinical picture.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test reveals predispositions in metabolic and GLP-1 signaling pathways that may help provide context for how your body processes glucose, regulates appetite, and responds to peptide-based therapies. This genetic information should be interpreted alongside clinical biomarkers—not as a replacement for provider evaluation.

Genetic variants such as GLP1R rs6923761 (associated with GLP-1 receptor sensitivity), GIPR rs1800437 (glucose-dependent insulinotropic peptide signaling), and FTO rs9939609 (fat mass and obesity predisposition) can support a more personalized conversation with your provider about treatment strategy. These predispositions do not predict exact medication response or guarantee weight loss; rather, they offer genetic context for informed decision-making.

Bringing genetic predisposition insights to your provider appointment—combined with current biomarker results and your medical history—enables a more comprehensive eligibility discussion. Your provider can then integrate genetic context, metabolic assessment, and clinical judgment to determine whether semaglutide aligns with your individual health profile and treatment goals.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Can I get semaglutide just because I want to lose weight, or do I need specific medical criteria?